Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma

Porębska, Irena; Kosacka, Monika; Sobańska, Ewa; Wyrodek, Ewa; Jankowska, Renata

doi:10.1007/5584_2015_121

Cited by 7 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the previous studies, using other methods for survivin quantification than plasma measurements, are controversial in this aspect: some researchers could not confirm an association with the histological type [ 10 ], while others reported higher survivin expression in squamous cell carcinoma than in adenocarcinoma [ 11 ]. On the contrary, Porebska et al [ 15 ] found lower survivin expressions in tissue samples of patients with squamous cell carcinoma, than those with lung adenocarcinoma, which is in line with our findings. Lower circulating survivin levels in squamous cell carcinoma might be in connection with the relatively moderate tendency to invasion and metastatization compared to other histological types.…”

Section: Discussionsupporting

confidence: 93%

“…Furthermore, survivin protein expression assessed by immunohistochemistry in lung cancer tissue specimens correlates with the grade of differentiation, the tumor stage and the presence of lymph node metastases [ 10 ]. However, there are controversial results about the relationship between survivin expression and histological types [ 10 , 11 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Puskás

Bikov

Horváth

et al. 2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The survivin protein contributes to the development and progression of tumors. Protein expression and mRNA levels correlate with clinicopathological parameters and survival of cancer patients. Our purpose was to evaluate whether circulating survivin levels have any diagnostic or predictive value in lung cancer. 118 patients with advanced stage lung cancer participated in our study. 53 suffered from adenocarcinoma (ADC), 33 from squamous cell carcinoma (SqCC), and 32 from small cell lung cancer (SCLC). We also enrolled 21 control subjects. Blood samples were collected before and after two cycles of chemotherapy. We measured survivin concentrations with ELISA. Non-parametric tests were used for analysis. We did not find significant difference in survivin levels between patients and control subjects (17.19/0–829.74/vs. 49.13/0–165.92/pg/ml; p = 0.07). We found lower survivin concentrations in patients with SqCC (0/0–171.24/pg/ml) than in those with ADC (24.94/0–626.46 pg/ml) and SCLC (45.51/0–829.74/pg/ml) (ADC vs. SqCC p < 0.0001, ADC vs. SCLC p = 0.0405, SqCC vs. SCLC p < 0.0001). Survivin levels were higher in stage IV patients than in patients without distant metastases (p = 0.0061), and concentrations were progressively higher with increasing number of metastatic organ sites (p = 0.04). We observed a decrease in survivin levels in ADC patients after platinum plus pemetrexed chemotherapy (26.22/0–626.46/pg/ml before vs. 0/0–114.36/pg/ml after; p = 0.01). Neither progression-free nor overall survival correlated with survivin levels at baseline. Our data imply that survivin may be involved in the development of metastases and it might be used as a biomarker of disease progression. However, circulating survivin concentrations do not predict survival of patients with lung cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Puskás

Bikov

Horváth

et al. 2021

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…30 , who observed less than 2% BAX expression in cSCC in felines. However, other human studies observed BAX expression in cSCC and pulmonary SCC, which ranged from 53–100% 59,60 . A recent study reported that BAX expression in normal keratinocytes in the dog epidermis ranged from very weak to moderate, highlighting the importance of this expression in the pathogenesis of diseases 61 .…”

Section: Discussionmentioning

confidence: 93%

Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma

Anjos

Bueno

Magalhães

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Canine cutaneous squamous cell carcinoma (cSCC) is the most common skin cancer in dogs, and, due to its low metastatic rate, local treatments, such as electrochemotherapy (ECT), promote disease control or even complete remission (CR). This study aimed to evaluate the gene and protein expression of Bcl-2 and Bcl-2 associated X protein (BAX), the proliferative index and clinical parameters in dogs with cSCC subjected to ECT. A prospective nonrandomized clinical study was performed using dogs with naturally occurring cSCC that was treated with ECT. Eighteen lesions from 11 dogs were selected. The tumor size at day 0 (D0) had no impact on survival or prognosis (P > 0.05). Tumor samples had a lower proliferative index after ECT (D21) than before ECT (P = 0.031). The survival of subjects with Ki67 values lower and higher than the Ki67 median value were not significantly different (P > 0.05). Regarding apoptotic markers, there were no significant differences in the gene and protein expression levels of BAX or Bcl-2 at D0 and D21 (P > 0.05) or in the overall survival of subjects with different levels of apoptotic markers. In conclusion, there was no change in BAX or Bcl-2 gene and protein expression in response to ECT at the time points evaluated, but ECT was able to reduce tumor volume and cellular proliferation in cSCC.

show abstract

“…Most of the NSCLC (80-90%) shows overexpression of survivin [90, 91]. Studies show a significantly higher level of survivin in SCC as compared to adenocarcinoma of lung, [92–94], where it contributes to poor prognosis and decreased patient survival [90, 95]. Higher nuclear survivin has been identified as an independent prognostic factor for lung SCC [95].…”

Section: Survivin Expression In Scc: Aggressiveness and Poor Prognosismentioning

confidence: 99%

Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma

Khan

Yadav

et al. 2017

Cell Mol Biol Lett

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) is the most common cancer worldwide. The treatment of locally advanced disease generally requires various combinations of radiotherapy, surgery, and systemic therapy. Despite aggressive multimodal treatment, most of the patients relapse. Identification of molecules that sustain cancer cell growth and survival has made molecular targeting a feasible therapeutic strategy. Survivin is a member of the Inhibitor of Apoptosis Protein (IAP) family, which is overexpressed in most of the malignancies including SCC and totally absent in most of the normal tissues. This feature makes survivin an ideal target for cancer therapy. It orchestrates several important mechanisms to support cancer cell survival including inhibition of apoptosis and regulation of cell division. Overexpression of survivin in tumors is also associated with poor prognosis, aggressive tumor behavior, resistance to therapy, and high tumor recurrence. Various strategies have been developed to target survivin expression in cancer cells, and their effects on apoptosis induction and tumor growth attenuation have been demonstrated. In this review, we discuss recent advances in therapeutic potential of survivin in cancer treatment.

show abstract

Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma

Cited by 7 publications

References 20 publications

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma

Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma

Contact Info

Product

Resources

About